Search Within

Andrea D. Basso

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (9)
Groups
  1. Department of Medicine (25)
  2. GSK Faculty (25)
  3. Genitourinary Oncology Service (25)
  4. Human Oncology and Pathogenesis Program (25)
  5. Solid Tumor Oncology Division (25)
  6. Breast Medicine Service (24)

More Groups

People
  1. David Solit (25)
  2. Neal Rosen (24)
  3. Pamela Munster (7)
  4. Howard Scher (6)
  5. Olivera Grbovic-Huezo (6)
  6. Ayana Sawai (5)

More People

Years
  1. 2006 (2)
  2. 2005 (3)
  3. 2004 (3)
  4. 2003 (6)
  5. 2002 (5)
  6. 2001 (4)

More Years

Publications
  1. Clinical Cancer Research (8)
  2. Cancer Research (5)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (4)
  4. Breast Cancer Research and Treatment (1)
  5. Chemistry and Biology (1)
  6. Current Cancer Drug Targets (1)

More Publications

Publishers
  1. American Association for Cancer Research (17)
  2. Elsevier Inc. (2)
  3. Nature Publishing Group (2)
  4. American Society for Biochemistry and Molecular Biology (1)
  5. Bentham Science Publishers (1)
  6. National Academy of Sciences (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ansamycins inhibit Akt activation and induce the 20S proteasomal degradation of Akt protein
    Meeting Abstract

    Basso, A. D.; Solit, D. B.; Rosen, N.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • 17-Allylamino-geldanamycin causes AKT inactivation and enhances the anti-tumor effects of paclitaxel
    Meeting Abstract

    Solit, D. B.; Basso, A. D.; Munster, P. N.; Norton, L.; Scher, H. I.; Rosen, N.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: The Biology Behind: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001
    Journal Article

    Munster, P. N.; Basso, A.; Solit, D.; Norton, L.; Rosen, N.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) inhibits intracellular Akt kinase activity in HER2 overexpressing breast cancer cell lines and enhances the apoptosis induced by cytotoxic agents
    Meeting Abstract

    Munster, P. N.; Basso, A.; Solit, D.; Rosen, N.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save
  • 17-allyl-amino-seldanamycin induces HER2 degradation and AKT inactivation in a human breast cancer xenograft model
    Meeting Abstract

    Solit, D.; Munster, P.; Basso, A.; Tong, W.; Agus, D.; Scher, H.; Norton, L.; Rosen, N.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save